Roivant Sciences Ltd. Common Shares (ROIV) — Analysis Summary
Roivant Sciences Ltd. Common Shares (ROIV) has a market cap of $29.63B with year-over-year revenue growth of -71.6%. Net margin stands at -3629.2%. The stock trades at a P/E ratio of -111.3.
Key Takeaways
- Revenue changed -71.6% year-over-year
- Net margin of -3629.2%
- P/E ratio of -111.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ROIV posted revenue growth of -71.6% and trades at a P/E of -111.3.
Roivant Sciences Ltd. Common Shares (ROIV)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -7914.8% — severe operating losses
Net margin at -3535.0% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
721
Headquarters
LONDON
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.